The platform now includes more comprehensive candidate screening and bioavailability enhancing tools, ADME considerations, in silico DMPK modeling, materials for cGLP intravenous and oral toxicological studies, and cGMP materials for first-inhuman studies. CONTRACT PHARMA COMPANY SHOWCASE: LEARN MORE ABOUT ...